Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
PLoS Med. 2009 Dec;6(12):e1000189. doi: 10.1371/journal.pmed.1000189. Epub 2009 Dec 1.
There is a paucity of data on the health care costs of antiretroviral therapy (ART) programmes in Africa. Our objectives were to describe the direct heath care costs and establish the cost drivers over time in an HIV managed care programme in Southern Africa.
METHODS/FINDINGS: We analysed the direct costs of treating HIV-infected adults enrolled in the managed care programme from 3 years before starting non-nucleoside reverse transcriptase inhibitor-based ART up to 5 years afterwards. The CD4 cell count criterion for starting ART was <350 cells/microl. We explored associations between variables and mean total costs over time using a generalised linear model with a log-link function and a gamma distribution. Our cohort consisted of 10,735 patients (59.4% women) with 594,497 mo of follow up data (50.9% of months on ART). Median baseline CD4+ cell count and viral load were 125 cells/microl and 5.16 log(10) copies/ml respectively. There was a peak in costs in the period around ART initiation (from 4 mo before until 4 mo after starting ART) driven largely by hospitalisation, following which costs plateaued for 5 years. The variables associated with changes in mean total costs varied with time. Key early associations with higher costs were low baseline CD4+ cell count, high baseline HIV viral load, and shorter duration in HIV care prior to starting ART; whilst later associations with higher costs were lower ART adherence, switching to protease inhibitor-based ART, and starting ART at an older age.
Drivers of mean total costs changed considerably over time. Starting ART at higher CD4 counts or longer pre-ART care should reduce early costs. Monitoring ART adherence and interventions to improve it should reduce later costs. Cost models of ART should take into account these time-dependent cost drivers, and include costs before starting ART. Please see later in the article for the Editors' Summary.
在非洲,抗逆转录病毒疗法(ART)项目的医疗保健费用数据很少。我们的目的是描述艾滋病毒管理护理计划中直接的医疗保健费用,并随着时间的推移确定成本驱动因素。
方法/发现:我们分析了从开始使用非核苷类逆转录酶抑制剂为基础的 ART 前 3 年至之后 5 年期间,接受管理护理计划治疗的感染艾滋病毒的成年患者的直接治疗费用。开始 ART 的 CD4 细胞计数标准为<350 个/μl。我们使用具有对数链接函数和伽马分布的广义线性模型,探索了变量与随时间变化的平均总费用之间的关联。我们的队列包括 10735 名患者(59.4%为女性),随访数据为 594497 个月(50.9%的 ART 治疗月)。中位基线 CD4+细胞计数和病毒载量分别为 125 个/μl 和 5.16 log(10) 拷贝/ml。在开始 ART 前后的时期,费用出现高峰(从开始 ART 的前 4 个月到后 4 个月),主要是由于住院治疗,此后 5 年费用保持稳定。与平均总费用变化相关的变量随时间而变化。与更高费用相关的早期关键因素是基线 CD4+细胞计数较低、基线 HIV 病毒载量较高以及开始 ART 前接受 HIV 护理的时间较短;而与更高费用相关的后期因素是较低的 ART 依从性、改用基于蛋白酶抑制剂的 ART 以及开始 ART 的年龄较大。
平均总费用的驱动因素随时间有很大变化。在更高的 CD4 计数或更长的 ART 前护理开始 ART 应降低早期成本。监测 ART 依从性并采取干预措施提高依从性应降低后期成本。ART 的成本模型应考虑这些随时间变化的成本驱动因素,并包括开始 ART 之前的成本。请在文章后面查看编辑摘要。